Semaglutide + Cagrilintide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 5 registered trials.

Why this status

  1. 27 May 2022: Trial registered, NCT05394519
  2. 1 Feb 2023: Trial started, NCT05394519
  3. 14 Nov 2023: Trial registered, NCT06131437
  4. 27 Nov 2023: Trial started, NCT06131437
  5. 17 Jan 2025: Trial registered, NCT06780449
  6. 10 Feb 2025: Trial started, NCT06780449

The trials

NCT05394519: A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

State
Completed
Phase
Phase 3
People
1,200 taking part
Started
1 Feb 2023
Primary completion
28 Jan 2025
Arms
CagriSema
Results
None posted
  1. 27 May 2022: Trial registered
  2. 1 Feb 2023: Trial started
  3. 3 Feb 2025: Trial completed

NCT06131372: A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

State
Completed
Phase
Phase 2
People
626 taking part
Started
1 Apr 2024
Primary completion
24 Sep 2025
Arms
CagriSema
Results
None posted
  1. 14 Nov 2023: Trial registered
  2. 1 Apr 2024: Trial started
  3. 6 Nov 2025: Trial completed

NCT06131437: A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

State
Completed
Phase
Phase 3
People
809 taking part
Started
27 Nov 2023
Primary completion
8 Dec 2025
Arms
CagriSema 2.4 mg/2.4 mg
Results
None posted
  1. 14 Nov 2023: Trial registered
  2. 27 Nov 2023: Trial started
  3. 9 Jan 2026: Trial completed

NCT06207877: A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

State
Completed
Phase
Phase 1
People
62 taking part
Started
23 Feb 2024
Primary completion
16 Oct 2024
Arms
CagriSema
Results
None posted
  1. 17 Jan 2024: Trial registered
  2. 23 Feb 2024: Trial started
  3. 22 Nov 2024: Trial completed

NCT06780449: A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

State
Under way
Phase
Phase 3
People
400 planned
Started
10 Feb 2025
Primary completion
28 Aug 2028
Arms
CagriSema
Results
None posted
  1. 17 Jan 2025: Trial registered
  2. 10 Feb 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.